The Lupus Research Alliance and Lupus Therapeutics support diversity in clinical trials to ensure that populations that test potential treatments reflect the population with the disease.

LRA joined 42 other members of the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) Coalition in sending a letter to Congresswoman Robin L. Kelly in support of the National Institutes of Health (NIH) Clinical Trial Diversity Act (H.R. 3503) that she sponsored. Read the letter sent to Congresswoman Kelly — Coalition Support Letter – NIH Clinical Trial Diversity Act Sign On Letter.

Learn more about the LRA’s advocacy efforts on Capitol Hill here Action Center – Fighting Lupus | Lupus Research Alliance